Dimensional Fund Advisors LP Sells 47,834 Shares of Illumina, Inc. (NASDAQ:ILMN)

Dimensional Fund Advisors LP decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 13.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 307,053 shares of the life sciences company’s stock after selling 47,834 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.19% of Illumina worth $32,056,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. Massachusetts Financial Services Co. MA bought a new stake in shares of Illumina in the 2nd quarter valued at about $44,349,000. Plato Investment Management Ltd boosted its stake in Illumina by 30.5% during the second quarter. Plato Investment Management Ltd now owns 4,073 shares of the life sciences company’s stock worth $425,000 after acquiring an additional 953 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in Illumina in the second quarter worth $649,000. Wilkins Investment Counsel Inc. increased its stake in Illumina by 63.7% in the second quarter. Wilkins Investment Counsel Inc. now owns 108,502 shares of the life sciences company’s stock valued at $11,325,000 after purchasing an additional 42,222 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in shares of Illumina by 1.1% during the second quarter. Envestnet Asset Management Inc. now owns 319,834 shares of the life sciences company’s stock valued at $33,384,000 after purchasing an additional 3,564 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Down 1.1 %

Shares of Illumina stock opened at $128.98 on Wednesday. The firm has a market cap of $20.55 billion, a PE ratio of -15.83 and a beta of 1.15. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $148.19. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a fifty day moving average price of $126.88 and a 200-day moving average price of $120.29.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The firm’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.32 earnings per share. Equities research analysts anticipate that Illumina, Inc. will post 3.63 EPS for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research reports. UBS Group raised their target price on Illumina from $131.00 to $133.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Piper Sandler decreased their price objective on Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Barclays raised Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 target price on the stock in a research report on Wednesday, August 14th. Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research report on Wednesday, August 28th. Finally, Scotiabank lowered their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $152.05.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.